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Abstract
Background: Pancreatic cancer is the fourth leading cause of death in the US. Unlike other solid tumors such as
testicular cancer which are now curable, more than 90% of pancreatic cancer patients die due to lack of response
to therapy. Recently, the level of 14-3-3s mRNA was found to be increased in pancreatic cancers and this
increased expression may contribute to the failure in treatment of pancreatic cancers. In the present study, we
tested this hypothesis.
Methods: Western blot analysis was used to determine 14-3-3s protein level in fresh frozen tissues and was
correlated to clinical outcome. A stable cell line expressing 14-3-3s was established and the effect of 14-3-3s over-
expression on cellular response to radiation and anticancer drugs were tested using SRB assay and clonogenic
assays. Cell cycle distribution and apoptosis analyses were performed using propidium iodide staining and PARP
cleavage assays.
Results: We found that 14-3-3s protein level was increased significantly in about 71% (17 of 24) of human
pancreatic cancer tissues and that the 14-3-3s protein level in cancers correlated with lymph node metastasis and
poor prognosis. Furthermore, we demonstrated that over-expression of 14-3-3s in a pancreatic cancer cell line
caused resistance to g-irradiation as well as anticancer drugs by causing resistance to treatment-induced apoptosis
and G2/M arrest.
Conclusion: The increased level of 14-3-3s protein likely contributes to the poor clinical outcome of human
pancreatic cancers by causing resistance to radiation and anticancer drugs. Thus, 14-3-3s may serve as a prognosis
marker predicting survival of pancreatic cancer patients and guide the clinical treatment of these patients.
Background
14-3-3s is a member of a highly conserved family of 14-
3-3 proteins that are present in all eukaryotic organisms.
There are 7 known human 14-3-3 isotypes (b, g, ε, h, ζ, s
and τ/θ) [1-3] and they play important roles in many bio-
logical activities by binding to and altering the subcellular
localization and/or stability of key molecules in various
signaling cascades [4,5]. 14-3-3s was originally character-
ized as a human mammary epithelium marker 1 [6] and
later rediscovered as an important molecule for cell cycle
checkpoint regulation [7,8].
Recently, proteomic profiling of a drug-selected breast
cancer cell line MCF7/AdVp3000 showed that the
expression of 14-3-3s was up-regulated and its expres-
sion correlates with the drug resistance level of a series
of drug resistant breast cancer cell lines [9]. Further
investigation indicated that the elevated expression of
14-3-3s causes resistance to anticancer drugs by resist-
ing drug-induced apoptosis and inducing cell cycle
arrest for repair of DNA damage [9,10].
Pancreatic cancer is the fourth leading cause of death
in the US. Unlike some other cancers such as testicular
cancer which are now curable, pancreatic cancer is
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incurable and more than 90% of pancreatic cancer
patients die due to lack of treatment response. 14-3-3s
has been reported to be one of a number of genes that
have increased expression at its mRNA level in pancrea-
tic cancer tissues as identified by microarray profiling
analyses [11-14]. Thus, it is possible that increased 14-3-
3s expression may contribute to the failure in treatment
of pancreatic cancers. In this study, we tested the
hypotheses that 14-3-3s is up-regulated in pancreatic
cancers at its protein level and its over-expression may
contribute to the failure of treatment of pancreatic
cancers by causing resistance to radiation and
chemotherapy.
Using fresh-frozen tissues combined with Western
blot analysis, we found that 14-3-3s expression was
indeed up-regulated in about 71% of human pancreatic
cancer tissues examined and that the 14-3-3s expression
level correlated with lymph node metastasis, consistent
with poor prognosis. Furthermore, over-expression of
ectopic 14-3-3s in a pancreatic cancer cell line caused
resistance to g-irradiation as well as anticancer drugs
gemcitabine, mitoxantrone and Adriamycin by causing




All studies involving human subjects have been con-
ducted in strict compliance with and approved by the
Institutional Review Board (IRB) of Indiana University
School of Medicine and its affiliated hospitals. All
patients on this study signed informed written consent
for collection of pancreatic tissues at the time of routine
operation per the Indiana University Pancreas Lesion
Tissue Fluid Bank (IUPLTFB) or IU/Lilly Tissue Bank
protocol approved by IRB as described above. Surgical
pathology was confirmed in all patients. Pancreatic can-
cer was staged according to the most current AJCC
Guidelines. The matching normal tissues were from the
farthest point (at least 20 mm) away from lesion
(tumor). Tissue specimens were aliquoted and frozen
immediately in liquid nitrogen after procurement and
stored at -80°C.
Sample preparation and Western blot analysis
Sample preparation and Western blot analysis were per-
formed as previously described [15]. Briefly, the frozen
tissues were thawed and homogenized in TNN-SDS buf-
fer (50 mM Tris-HCl, pH value 7.5, 150 mM NaCl, 0.5%
Nonidet P-40, 50 mM NaF, 1 mM sodium orthovana-
date, 1 mM dithiothreitol, 0.1% SDS, and 2 mM phenyl-
methylsulfonyl fluoride) by using pellet pestle (Fisher
scientific) and the lysates were clarified by centrifugation
(12,000 g for 30 min at 4°C).
The tissue or cell lysates were separated by SDS-
PAGE and transferred to a PVDF membrane followed
by a 2-hr incubation in blocking solution (Tris- or PBS-
buffered saline containing 5% nonfat dried milk and
0.1% Tween 20) and a 2-hr incubation with monoclonal
antibody against 14-3-3s (Upstate, NY. 1:500 dilution).
The antibody reaction was detected by horseradish per-
oxidase-conjugated anti-mouse IgG antibody and visua-
lized using ECL. The relative intensity of the protein on
Western blot was measured using AlphaEaseFC Analysis
tools (Alpha Innotech).
Cell lines and stable transfection
BxPc-3 cells (ATCC) were grown in RPMI1640 (Cellgro)
supplemented with 10% fetal bovine serum (Gibco) and
1% penicillin/streptomycin mixture (BioWhittaker). Mia-
PaCa-2 cells (ATCC) were maintained in DMEM sup-
plemented with 10% fetal bovine serum, 2.5% donor
equine serum (HyClone), and 1% penicillin/streptomycin
mixture.
The cDNA of 14-3-3s was engineered into pcDNA3.1
(+) (Invitrogen). Transfection of this plasmid and its
vector control into MiaPaCa-2 cells were performed
using Lipofectamine (Invitrogen) and stable clones were
selected using 1 mg/ml G418 (Invitrogen) as previously
described [9,10]. The stable clones were maintained in
complete DMEM supplemented with 200 μg/ml G418.
For survival and apoptosis assays, G418 was removed
and the cells were maintained in G418-free medium for
one week prior to the assays.
Similarly, the stable siRNA knockdown BxPc-3 cells
were generated as previously described [9,10]. Briefly,
BxPc-3 cells were transfected with pSilencer-s (14-3-3s
shRNA cloned into pSilencer 3.1-H1neo vector) or
scrambled shRNA construct [9,10] using lipofectamine
followed by selection first with 100 μg/ml G418 for 3
days and cultured for one week in complete medium in
the absence of G418. The cells were then selected with
1 mg/ml G418 for 2 weeks. Individual clones were
tested for 14-3-3s knockdown and positive clones were
propagated and maintained in complete RPMI1640
medium.
Cytotoxicity assay
Cytotoxicity assay was performed as previously
described using sulforhodamine B (SRB) colorimetric
[16] and clonogenic [17] assays. For SRB assay, cells
were seeded in 96-well plate at 5000 cells/well and cul-
tured for 24 hours followed by treatment with antican-
cer drugs such as Adriamycin, mitoxantrone,
gemcitabine or g-irradiation and cultured continuously
for 3 days. The culture medium was then aspirated, and
the cells were fixed and stained by addition of 0.4%
(w/v) SRB (Sigma) in 1% acetic acid solution followed
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by incubation at room temperature for 20 minutes. Free
SRB was removed by washing cells with 1% acetic acid 3
times. The bound SRB was then solubilized with 10 mM
Tris-base, and the OD570 nm was determined using a 96-
well plate reader (MRX, Dynex Technologies).
For clonogenic assay, cells were seeded in 6-well plate
at 100-200 cells/well and cultured for 24 hours followed
by irradiation treatment. The cells were then cultured
for two weeks before being subjected to fixation and
staining with crystal violent (0.005% in 20% methanol)
for 30 min. The colonies were counted manually. The
radiation enhancement factor was calculated as the ratio
of the mean inactivation dose of control cells divided by
the mean inactivation dose of 14-3-3s over-expression
and knockdown cells as previously described [18]. A
value greater or less than 1 indicates significant radio-
sensitization or -resistance, respectively.
Cell cycle analysis
Cell cycle analysis was performed as previously
described [10]. Briefly, 5 × 105 cells were seeded in a
10-cm dish and cultured for 24 hours followed by treat-
ments with g-irradiation (5 Gy) or mitoxantrone
(10 nM) and continuing culture for 24 hours (g-irradia-
tion) or 72 hours (mitoxantrone). The cells were then
harvested, washed, and fixed using ethanol followed by
staining with propidium iodide and FACS analysis. Cell
cycle profiles were determined using CELL Quest and
ModiFit programs.
Statistical analysis
Data analyses were performed with GraphPad Prism
(GraphPad Software Inc.) and Excel 2004 (Microsoft,
Seattle, WA). Statistical associations between categorical
factors were assessed using the Fisher exact test. Survi-
val time was measured from the time of surgery until
death or last follow-up (censor date was March 1, 2009).
The association of categorical factors with survival was
assessed using the Kaplan-Meier method and was ana-
lyzed using the log-rank test. Statistical significance was
set at p value < 0.05.
Results
14-3-3s protein level is up-regulated in human pancreatic
cancers
To determine the status of 14-3-3s expression at its
protein level in human pancreatic cancers relative to the
corresponding normal tissues, we collected 24 pairs of
fresh-frozen normal and cancer pancreatic tissues and
determined the protein level of 14-3-3s in these samples
using Western blot. The relative 14-3-3s protein level
was then determined. As shown in Figure 1A, 17 of the
24 cases (70.8%) show increased 14-3-3s expression in
cancers compared to their matching normal pancreatic
tissues. This increase is statistically significant (Figure
1B). In many cases, the increase is dramatic with one
case (#114) demonstrating ~46-fold increase in cancer
compared to normal tissues. Of the 24 cases, 4 (16.7%)
(#149, #71, #7, #309-03) have decreased 14-3-3s expres-
sion in cancer tissues whereas the remaining 3 (12.5%)
(#56, #43, and #303-20) show no observable differences
between normal and cancer tissues. These data clearly
indicate that the 14-3-3s protein level is significantly
increased in the majority of pancreatic cancer tissues
compared to their corresponding normal tissues.
Up-regulated 14-3-3s expression correlates with lymph
node metastasis and mortality
We next examined if the protein level of 14-3-3s in
pancreatic cancers correlates with lymph node metasta-
sis, an indicator of poor prognosis. For this purpose,
additional frozen tissues of pancreatic cancers were
collected without matching normal tissues. These
additional samples are 6-48, 7-39, 8-35, 202-47, 303-11,
310-03, 405-12, 405-58, 503-03, 507-17, 510-65, 512-42,
605-55, 607-10, and 608-12 (see Figure 2). This repre-
sents a total of 38 pancreatic cancer tissues of which 17
have lymph node metastasis and 21 do not (Table 1).
The 14-3-3s protein level was then determined using
Western blot in all these cancer tissues relative to a
known pancreatic cancer cell line, BxPc-3, which
expresses endogenous 14-3-3s (Figure 2). The relative
expression level of 14-3-3s in all cancer tissues was
then correlated with the status of lymph node metasta-
sis. As shown in Table 1, 52.9% of cancer tissues with
lymph node metastasis whereas only 19.0% of cancer tis-
sues without lymph node metastasis have high 14-3-3s
expression, a statistically significant difference (Table 1).
Thus, higher expression level of 14-3-3s correlates with
lymph node metastasis.
Next, a correlation analysis between patient survival
and 14-3-3s protein level was performed. As shown in
Figure 3, the Kaplan-Meier survival curves demonstrate
a trend of higher survival for the low expression group
compared to the high expression group (p = 0.06).
Over-expression of 14-3-3s causes resistance to radiation
and anticancer drugs
To determine if 14-3-3s expression is related to treat-
ment resistance in pancreatic cancer, we first tested the
treatment response of MiaPaCa-2, which does not
express detectable level of 14-3-3s, and BxPc-3, which
expresses high levels of endogenous 14-3-3s (Figure
4A). As shown in Figure 4B, BxPc-3 appears to be more
resistant to g-irradiation than MiaPaCa-2 cells, with
more surviving cells after irradiation treatment. Figure
4C and 4D show that BxPc-3 cells are also much more
resistant to anticancer drugs Adriamycin and
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mitoxantrone than MiaPaCa-2 cells. Clearly, the 14-3-3s
expression levels in these two pancreatic cancer cell
lines positively correlate with their level of radiation and
drug resistance.
To determine if 14-3-3s expression causes drug resis-
tance in pancreatic cancer cells, we established a stable
MiaPaCa-2 cell line over-expressing ectopic 14-3-3s
(Figure 5A) and then tested its response to g-irradiation
first using clonogenic assay. As shown in Figure 5B, the
stable 14-3-3s-over-expressing cells appear to be more
resistant to g-irradiation than the vector-transfected
(Vec) control cells with a radiation enhancement factor
of 0.79. Thus, over-expression of 14-3-3s in MiaPaCa-2
cells causes a significant increase in resistance to
g-irradiation.
We next investigated if over-expression of 14-3-3s
causes resistance to the anticancer drugs gemcitabine,
mitoxantrone, and Adriamycin. As shown in Figure 5C,
the stable 14-3-3s-over-expressing cells are significantly
more resistant to all three anticancer drugs compared
with the stable vector-transfected control clone. Thus,
ectopic over-expression of 14-3-3s causes both radiation
and drug resistance in MiaPaCa-2 cells.
To verify the above observations, we created a 14-3-3s
knockdown cell clone from BxPc-3 cells (Figure 5D) and
tested if knocking down 14-3-3s would decrease the
resistance of BxPc-3 cells to radiation and drug treat-
ment. As shown in Figure 5E and 5F, the stable clone
with 14-3-3s knockdown is significantly less resistant to
g-irradiation (with a radiation enhancement factor of
1.7), as well as to gemcitabine, Adriamycin, and mitox-
antrone than the control cells transfected with
scrambled control shRNAs. This finding further sup-
ports the conclusion that 14-3-3s over-expression con-
tributes to treatment resistance in pancreatic cancer
cells.
14-3-3s increases cell cycle arrest upon DNA damage
Previously, we observed that over-expression of 14-3-3s
increases G2/M arrest upon DNA damage in prostate
cancer cells as a mechanism of survival, by allowing more
time to repair DNA damage [10]. To determine if the
over-expression of 14-3-3s also causes similar G2/M
arrest upon DNA damage in pancreatic cancer cells, we
treated the stable 14-3-3s-over-expressing and vec-trans-
fected control cells with g-irradiation or mitoxantrone
followed by FACS analysis of cell cycle distribution. As
shown in Figure 6A, the stable 14-3-3s-over-expressing
cells clearly have a much higher proportion of cells
arrested at G2/M than the vector-transfected control
Figure 1 14-3-3s expression in paired normal and cancer pancreas. A, Western blot analysis. Lysates from fresh frozen matching human
normal (N) and pancreatic ductal adenocarcinoma (C) tissues were separated by SDS-PAGE followed by Western blot analysis of 14-3-3s and
GAPDH control. The relative level (R.L.) of 14-3-3s in each sample was measured and normalized to that of GAPDH. The level of 14-3-3s in each
normal tissue was set to 1. B, summary of Western blot analysis. The relative levels of 14-3-3s in normal and cancer tissues were graphed with
the median level in each group marked by (-). Statistical analysis was done using Student T-test.
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cells following g-irradiation or mitoxantrone treatment.
Thus, in pancreatic cancer cells 14-3-3s likely provides a
protection mechanism by arresting cells at G2/M phase,
thereby providing cells an opportunity to repair DNA
damage and survive DNA-damaging treatments.
14-3-3s over-expression causes resistance to treatment-
induced apoptosis
We next examined if the increased resistance of the
stable 14-3-3s-over-expressing cells was also due to inhi-
bition of treatment-induced apoptosis. For this purpose,
we first examined the population of stable 14-3-3s-over-
expressing and vector-transfected control cells at the
subG1 phase following g-irradiation. As shown in Figure
6B, the stable 14-3-3s-over-expressing cells clearly have
much fewer cells at the subG1 phase compared with the
vector-transfected control cells following g-irradiation.
We next examined the cleavage of PARP, a target sub-
strate of activated caspases, following treatment with g-
irradiation or with the anticancer drug mitoxantrone. As
shown in Figure 6C, the cleaved 85-kDa fragment of
PARP is produced only in the control vector-transfected
Figure 2 Correlation of 14-3-3s expression in pancreatic cancer tissues with lymph node metastasis. Thirty-eight fresh frozen human
pancreatic ductal adenocarcinoma tissues with (+) or without (-) lymph node (LN) metastasis were analyzed using Western blot for the protein
level of 14-3-3s and GAPDH control. The relative level (R.L.) of 14-3-3s in each sample was measured and normalized to that of GAPDH. In each
gel, lysates from BxPc-3 (BxPc) cells were used as a control and the level of 14-3-3s in BxPc-3 cells was set to 1.
Table 1 Correlation between 14-3-3s expression and
lymph node metastasis
Cancer Tissue 14-3-3s expression levela Total P valueb
High Low
Lymph Node (+) 9 (52.9%) 8 (47.1%) 17 0.04
Lymph Node (-) 4 (19.0%) 17 (81.0%) 21
Total 13 25 38
aThe expression level was designated high if the staining intensity is above
0.68 and low if equal to or below 0.68 in a post hoc analysis.
bTwo-sided Fisher’s exact test was used.
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cells following g-irradiation. Production of the 85-kDa
fragment by g-irradiation is apparently inhibited by
over-expression of 14-3-3s. Figure 6D shows that
mitoxantrone-induced production of the 85-kDa frag-
ment of PARP is also inhibited by 14-3-3s over-
expression in the stable 14-3-3s-over-expressing cells
compared with the vector-transfected control. Together,
these findings suggest that over-expression of 14-3-3s
in pancreatic cancer cells likely causes resistance to
DNA-damage induced apoptosis and, thus, resistance to
radiation and drug treatments.
Discussion
In this study, we demonstrated that the 14-3-3s protein
level was increased in a majority of pancreatic cancer tis-
sues studied (~71%) compared to their corresponding
normal tissues and that the 14-3-3s protein level corre-
lated with lymph node metastasis and patient survival.
We also showed that the increased expression of 14-3-3s
correlated with poor cellular response to g-irradiation
and anticancer drugs and that stable over-expression of
ectopic 14-3-3s in a human pancreatic cancer cell line,
MiaPaCa-2, significantly increased its resistance level to
g-irradiation as well as anticancer drugs in part by caus-
ing resistance to the apoptosis induced by the treatments
and by arresting cells in G2/M phase.
It has been reported that 14-3-3s expression is lost or
decreased in human cancers of breast [19,20], liver [21],
vulva [22], mouth [23], as well as neuroendocrine tumors
Figure 3 Correlation of 14-3-3s expression in pancreatic cancer
tissues with patient survival. Using Kaplan-Meier analysis, the high
14-3-3s expression group has a trend of lower survival rate than the
low expression group (p = 0.06, Log-Rank test).
Figure 4 Relationship between 14-3-3s expression and drug resistance of pancreatic cancer cell lines. A, Expression level of 14-3-3s in
BxPc-3 and MiaPaCa-2 cells. Lysates from BxPc-3 or MiaPaCa-2 cells were prepared for Western blot analyses of 14-3-3s and actin as a loading
control. B, C, and D, Correlation of 14-3-3s expression and treatment resistance. The effect of g-irradiation (B) and anticancer drugs Adriamycin
(C) and mitoxantrone (D) on the survival of BxPc-3 and MiaPaCa-2 cells was determined using SRB assay. The survival following treatments was
normalized to the control without irradiation or drug treatment.
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[24], and small and non-small cell lung [25,26] cancers.
This decrease is thought to be due to hypermethylation
of the CpG islands of the 14-3-3s gene [19,25,27,28].
However, recent studies revealed that the loss of 14-3-3s
expression in breast cancers is a sporadic event and that
its expression is up-regulated in some breast tumors
[29,30]. From these later studies, it appears that majority
of breast cancer cells with basal/myoepithelial phenotype
show 14-3-3s expression whereas some of the breast
cancer cells with luminal epithelial cell differentiation
show decreased or loss of 14-3-3s expression. Further-
more, it has also been reported that 14-3-3s expression
is increased in lung cancers [31], and head and neck
squamous cell carcinomas [32].
In this study, we demonstrated that 14-3-3s protein
was increased significantly in the majority (17 of 24) of
paired fresh-frozen pancreatic cancer tissues examined.
Previously, it has also been observed that 14-3-3s is one
of the genes with increased expression at the mRNA level
in pancreatic cancer tissues using microarray profiling or
real time PCR [11-13,33]. In the study by Friess et al.
[11], a microarray analysis of 5600 human genes in 8
human pancreatic ductal adenocarcinomas and 8 normal
tissues showed that 14-3-3s is one of 120 genes that had
increased expression at the mRNA level in cancer com-
pared to normal tissues. Similarly, Iacobuzio-Donahue et
al. [13] reported that 14-3-3s is one of the genes with
increased expression of mRNA in a cDNA microarray
profiling study of 17 infiltrating pancreatic cancer tissues
compared with 5 normal pancreatic tissues. Using cell
lines and methylation specific PCR analysis it was found
that the increased expression of 14-3-3s mRNA in pan-
creatic cancer cells may be due to hypomethylation of its
promoter region. This later observation is interesting
since 14-3-3s in other cancers such as breast cancer is
likely to be hypermethylated, resulting in silencing of its
expression. Again in a third study, Logsdon et al. [12]
used microarray analysis of 10 pancreatic cancer and 5
normal tissues and found 14-3-3s among 188 genes that
had increased mRNA expression in pancreatic cancer
Figure 5 14-3-3s over-expression causes resistance to g-irradiation and anticancer drugs in pancreatic cancer cell lines. A, Western blot
analysis. Lysates from MiaPaCa-2 cells stably transfected with 14-3-3s or vector control were prepared for Western blot analyses of 14-3-3s and
actin as a control. B, Effect of 14-3-3s over-expression on radiation resistance. Clonogenic assay was used to determine the response of MiaPaCa-
2 stable clones transfected with 14-3-3s or vector control (Vec.) to g-irradiation (IR). C, Effect of 14-3-3s over-expression on drug resistance. SRB
assay was used to determine the response of MiaPaCa-2 stable clones transfected with 14-3-3s or vector control (Vec.) to anticancer drugs
gemcitabine (GEM), mitoxantrone (MX), and Adriamycin (Adr). RRF = relative resistance factor derived by dividing the IC50 of 14-3-3s-expressing
cells by that of the vector-transfected control cells. D, Western blot analysis. Lysates from BxPc-3 cells stably transfected with 14-3-3s or
scrambled shRNA control were prepared for Western blot analyses of 14-3-3s and actin as a control. E and F, Effect of 14-3-3s knockdown on
treatment resistance. SRB assay was used to determine the response of BxPc-3 stable clone transfected with 14-3-3s or scrambled (Scr) shRNA
control to g-irradiation and anticancer drugs. RRF = relative resistance factor derived by dividing the IC50 of 14-3-3s-knockdown cells by that of
the scrambled control cells. (* = p value < 0.05; ** = p value < 0.01).
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tissues. Using laser capture dissection and real time PCR,
Neupane and Korc [33] compared the mRNA levels of all
seven 14-3-3 genes in 3 normal and 5 pancreatic ductal
adenocarcinoma tissues and found that 14-3-3s is the
only gene that has significantly higher expression in can-
cer tissues. However, all the above studies evaluated the
expression of 14-3-3s at its mRNA level. Since the
mRNA level does not always predict the protein level, we
performed the current study to determine 14-3-3s pro-
tein expression in pancreatic cancers and found that the
14-3-3s protein level is indeed significantly increased in
pancreatic cancers. This observation is consistent with a
previous study by Hustinx et al. [34]. Taken together,
these studies clearly show that 14-3-3s expression is
increased at both its mRNA and protein levels in pan-
creatic cancer tissues and the increase may be due to
decreased methylation of its promoter.
The finding that the 14-3-3s protein level is increased
in pancreatic cancers is interesting considering that
increased 14-3-3s expression has been shown to cause
drug resistance in breast and prostate cancer cell lines
[9,10]. Indeed, we showed that the increased 14-3-3s
expression in pancreatic cancers appears to correlate
with lymph node metastasis, a marker of poor prognosis,
and poor survival in a post hoc analysis. Furthermore,
over-expression of ectopic 14-3-3s in a pancreatic can-
cer cell line, MiaPaCa-2, caused resistance to anticancer
drugs as well as to g-irradiation while knocking down its
expression in BxPc-3 cells reduced the resistance. Thus,
the increased 14-3-3s expression in pancreatic cancer
cells may contribute to the failure in the treatment of
human pancreatic cancers. Clearly, a more extensive
prospective study with more patient samples is needed
to further warrant this conclusion.
Figure 6 14-3-3s over-expression increased drug-induced G2/M arrest and resistance to drug-induced apoptosis. A, Cell cycle
distribution analysis. Vector- and 14-3-3s-transfected stable MiaPaCa-2 cells were treated with 5 Gy g-irradiation (IR), 10 nM mitoxantrone, or
control without treatment followed by analysis of cell cycle distribution using FACS. B, Effect of 14-3-3s radiation-induced apoptosis. Vector- and
14-3-3s-transfected stable MiaPaCa-2 cells were treated with (filled bars) or without (white bars) g-irradiation followed by analysis of cells at sub-
G1 phase using FACS. C and D, Effect of 14-3-3s on radiation- and drug-induced PARP cleavage. Vector- and 14-3-3s-transfected stable
MiaPaCa-2 cells were treated with 20 Gy g-irradiation (C) or 10 μM mitoxantrone (D) for the times indicated followed by analysis of PARP
cleavage using Western blot analysis. The graph in panel D shows the rate of production of the 85-kDa PARP fragments product (as a ratio of
the 85-kDa fragment to the full-length 115-kDa protein).
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Recently, it has also been found that patients with breast
carcinomas (both luminal or basal/myoepithelial pheno-
types) that have higher cytoplasmic staining of 14-3-3s
also have shorter survival compared with patients whose
tumors have lower 14-3-3s staining [30]. In estrogen
receptor positive tumors, the relationship between 14-3-
3s and poor prognosis is even more significant. This later
finding is interesting because it has been shown previously
that estrogen regulates the stability of 14-3-3s by affecting
its proteosome-mediated degradation [35]. In another
study of cyclin B1 expression in breast carcinoma, Suzuki
et al. also showed that the expression of cyclin B1 and 14-
3-3s have a positive correlation and predict a poor prog-
nosis [36]. In a third study, it was suggested that 14-3-3s
expression is an independent prognostic marker for poor
survival of colorectal cancer patients [37]. In prostate can-
cers, we previously found an increase in 14-3-3s expres-
sion as tumor progresses [38]. Adenocarcinomas with high
Gleason scores (>7) had significantly higher staining inten-
sities and higher percentages of 14-3-3s immunoreactive
cells than adenocarcinomas with low scores (<7). Adeno-
carcinomas with lymph node metastases had higher per-
centages of 14-3-3s expression compared with
adenocarcinomas without lymph node metastases. Thus,
over-expression of 14-3-3s may cause resistance to thera-
pies in various cancers. However, it is noteworthy that
opposite observations have also been made in endometrial
cancer [39], head and neck cancer [40], NSCLC [41], and
nasopharyngeal carcinoma [42] where it was found that
the absence or low expression level of 14-3-3s predicts
poor survival. The reason for the difference between these
cancers is currently unknown.
Several popular anticancer drugs used for cancer ther-
apy such as mitoxantrone and Adriamycin are topo II
inhibitors which exert their anti-neoplastic effects in
susceptible cells by inducing apoptosis, mainly through
their ability to induce DNA double-strand breaks. Simi-
larly, g-irradiation also causes apoptosis via inducing
double strand DNA breaks. However, radiation has also
been suggested to induce cell death via mitotic cata-
strophe. In response to a DNA double-strand break,
cancer cells undergo apoptosis or go into cell cycle
arrest for repair of DNA which prevents replication of
damaged DNA or aberrant mitosis which leads to mito-
tic catastrophe and apoptosis, thereby, attenuating the
toxic effect of the treatments. 14-3-3s has been shown
to be essential for maintaining G2, G1, S cell cycle
arrest following DNA damage by interacting with and
negatively regulating cyclin dependent kinase Cdc2,
CDK2 and CDK4, which are responsible for cell cycle
progression, and prevent mitotic catastrophe and apop-
tosis [8,10,43]. Cells without 14-3-3s are unable to
arrest their cell cycle progression and will undergo
mitotic catastrophe and apoptosis following DNA
damage [43]. Furthermore, 14-3-3s interacts and nega-
tively regulates Bax and possibly BAD, two pro-apopto-
tic proteins that regulate the release of mitochondria
apoptogenic factors [44]. Thus, increased 14-3-3s
expression in pancreatic cancer cells likely causes resis-
tance to DNA damage-induced cell death.
Gemcitabine, a commonly used drug for pancreatic
cancer treatment, does not cause DNA double strand
breaks. However, incorporation of gemcitabine into
DNA also causes damage to DNA by generating prema-
ture termination of DNA replication. The observation
that over-expression of ectopic 14-3-3s increases while
knocking down its expression reduces resistance to
gemcitabine, suggests that 14-3-3s may also play a role
in regulating repair of premature terminations.
Conclusion
14-3-3s expression is clearly up-regulated in the major-
ity of pancreatic cancers and it may play an important
role in pancreatic cancer cell response to drug and
radiation treatments and, thus, likely contributes to the
failure in treatment of pancreatic cancers. 14-3-3s may
serve as a prognosis marker predicting survival of pan-
creatic cancer patients and help physician make critical
treatment decisions. Future studies targeting 14-3-3s for
development of chemosensitizers may help better treat
pancreatic cancers in combinational therapy.
Author details
1Department of Pharmacology and Toxicology, Indiana University School of
Medicine, Indianapolis, IN 46202, USA. 2Department of Surgery, Indiana
University School of Medicine, Indianapolis, IN 46202, USA. 3Department of
Biochemistry & Molecular Biology, Indiana University School of Medicine,
Indianapolis, IN 46202, USA. 4IU Simon Cancer Center, Indiana University
School of Medicine, Indianapolis, IN 46202, USA.
Authors’ contributions
ZL performed studies of cell lines. ZD performed studies with human tissues.
DM, MYS, JL, and PC participated in the studies with either cell lines and/or
human tissues. CMS participated in design and coordination of studies with
human tissues. JTZ conceived of the study, participated in its design and
coordination and drafted the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 22 June 2010 Accepted: 1 November 2010
Published: 1 November 2010
References
1. Fu H, Subramanian RR, Masters SC: 14-3-3 proteins: structure, function,
and regulation. Annu Rev Pharmacol Toxicol 2000, 40:617-647.
2. Berg D, Holzmann C, Riess O: 14-3-3 proteins in the nervous system. Nat
Rev Neurosci 2003, 4(9):752-762.
3. Li Z, Liu J-Y, Zhang J-T: 14-3-3σ, the double-edged sword of human
cancers. American Journal of Translational Research 2009, 1(4):326-340.
4. Muslin AJ, Xing H: 14-3-3 proteins: regulation of subcellular localization
by molecular interference. Cell Signal 2000, 12(11-12):703-709.
Li et al. BMC Cancer 2010, 10:598
http://www.biomedcentral.com/1471-2407/10/598
Page 9 of 11
5. van Hemert MJ, Steensma HY, van Heusden GP: 14-3-3 proteins: key
regulators of cell division, signalling and apoptosis. Bioessays 2001,
23(10):936-946.
6. Prasad GL, Valverius EM, McDuffie E, Cooper HL: Complementary DNA
cloning of a novel epithelial cell marker protein, HME1, that may be
down-regulated in neoplastic mammary cells. Cell Growth Differ 1992,
3(8):507-513.
7. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S,
Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/
M progression. Mol Cell 1997, 1(1):3-11.
8. Laronga C, Yang HY, Neal C, Lee MH: Association of the cyclin-dependent
kinases and 14-3-3 sigma negatively regulates cell cycle progression. J
Biol Chem 2000, 275(30):23106-23112.
9. Liu Y, Liu H, Han B, Zhang JT: Identification of 14-3-3sigma as a
contributor to drug resistance in human breast cancer cells using
functional proteomic analysis. Cancer Res 2006, 66(6):3248-3255.
10. Han B, Xie H, Chen Q, Zhang JT: Sensitizing hormone-refractory prostate
cancer cells to drug treatment by targeting 14-3-3sigma. Mol Cancer Ther
2006, 5(4):903-912.
11. Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-
Olson JF, Korc M, Hammer J, Buchler MW: Microarray-based identification
of differentially expressed growth- and metastasis-associated genes in
pancreatic cancer. Cell Mol Life Sci 2003, 60(6):1180-1199.
12. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK,
Giordano TJ, Misek DE, Kuick R, Hanash S: Molecular profiling of pancreatic
adenocarcinoma and chronic pancreatitis identifies multiple genes
differentially regulated in pancreatic cancer. Cancer Res 2003,
63(10):2649-2657.
13. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C,
Walter K, Sato N, Parker A, Ashfaq R, et al: Exploration of global gene
expression patterns in pancreatic adenocarcinoma using cDNA
microarrays. Am J Pathol 2003, 162(4):1151-1162.
14. Guweidhi A, Kleeff J, Giese N, Fitori JE, Ketterer K, Giese T, Buchler MW,
Korc M, Friess H: Enhanced expression of 14-3-3sigma in pancreatic
cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis
2004, 25(9):1575-1585.
15. Liu Z, Dong Z, Yang Z, Chen Q, Pan Y, Yang Y, Cui P, Zhang X, Zhang JT:
Role of eIF3a (eIF3 p170) in intestinal cell differentiation and its
association with early development. Differentiation 2007, 75(7):652-661.
16. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH: Optimization of
the sulforhodamine B colorimetric assay. J Immunol Methods 1997,
208(2):151-158.
17. Xu J, Peng H, Chen Q, Liu Y, Dong Z, Zhang JT: Oligomerization domain
of the multidrug resistance-associated transporter ABCG2 and its
dominant inhibitory activity. Cancer Res 2007, 67(9):4373-4381.
18. Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS:
Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic
cancer cells. Transl Oncol 2008, 1(1):36-43.
19. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H,
Marks JR, Lambers AR, Futreal PA, Stampfer MR, et al: High frequency of
hypermethylation at the 14-3-3 sigma locus leads to gene silencing in
breast cancer. PNAS 2000, 97(11):6049-6054.
20. Vercoutter-Edouart A-S, Lemoine J, Le Bourhis X, Louis H, Boilly B,
Nurcombe V, Revillion F, Peyrat JP, Hondermarck H: Proteomic analysis
reveals that 14-3-3sigma Is down-regulated in human breast cancer
cells. Cancer Res 2001, 61(1):76-80.
21. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S,
Ozeki I, Karino Y, et al: Frequent hypermethylation of CpG islands and
loss of expression of the 14-3-3 sigma gene in human hepatocellular
carcinoma. Oncogene 2000, 19(46):5298-5302.
22. Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, Dunne B,
Gusterson B, Evans DJ, Crook T: Coincident inactivation of 14-3-3sigma
and p16INK4a is an early event in vulval squamous neoplasia. Oncogene
2002, 21(12):1876-1881.
23. Gasco M, Bell AK, Heath V, Sullivan A, Smith P, Hiller L, Yulug I, Numico G,
Merlano M, Farrell PJ, et al: Epigenetic inactivation of 14-3-3 sigma in oral
carcinoma: association with p16(INK4a) silencing and human
papillomavirus negativity. Cancer Res 2002, 62(7):2072-2076.
24. Yatabe Y, Osada H, Tatematsu Y, Mitsudomi T, Takahashi T: Decreased
expression of 14-3-3sigma in neuroendocrine tumors is independent of
origin and malignant potential. Oncogene 2002, 21(54):8310-8319.
25. Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, Tezel E,
Takada M, Takahashi T: Frequent and histological type-specific
inactivation of 14-3-3sigma in human lung cancers. Oncogene 2002,
21(15):2418-2424.
26. Liu Y, Chen Q, Zhang JT: Tumor suppressor gene 14-3-3sigma is down-
regulated whereas the proto-oncogene translation elongation factor
1delta is up-regulated in non-small cell lung cancers as identified by
proteomic profiling. J Proteome Res 2004, 3(4):728-735.
27. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K: Inactivation of the
14-3-3sigma Gene Is Associated with 5’ CpG Island Hypermethylation in
Human Cancers. Cancer Res 2000, 60(16):4353-4357.
28. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S:
Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast
cancer. Oncogene 2001, 20(26):3348-3353.
29. Benzinger A, Muster N, Koch HB, Yates JR, Hermeking H: Targeted
proteomic analysis of 14-3-3sigma, a p53 effector commonly silenced in
cancer. Mol Cell Proteomics , 3 2005, 4(6):785-795.
30. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Steele D, Cossu A,
Budroni M, Palmieri G, Lakhani SR: Distribution and significance of 14-3-
3sigma, a novel myoepithelial marker, in normal, benign, and malignant
breast tissue. J Pathol 2004, 202(3):274-285.
31. Nakanishi K, Hashizume S, Kato M, Honjoh T, Setoguchi Y, Yasumoto K:
Elevated expression levels of the 14-3-3 family of proteins in lung
cancer tissues. Hum Antibodies 1997, 8(4):189-194.
32. Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, Reed SG:
Identification of genes overexpressed in head and neck squamous cell
carcinoma using a combination of complementary DNA subtraction and
microarray analysis. Laryngoscope 2000, 110(3 Pt 1):374-381.
33. Neupane D, Korc M: 14-3-3sigma modulates pancreatic cancer cell
survival and invasiveness. Clin Cancer Res 2008, 14(23):7614-7623.
34. Hustinx SR, Fukushima N, Zahurak ML, Riall TS, Maitra A, Brosens L,
Cameron JL, Yeo CJ, Offerhaus GJ, Hruban RH, et al: Expression and
prognostic significance of 14-3-3sigma and ERM family protein
expression in periampullary neoplasms. Cancer Biol Ther 2005,
4(5):596-601.
35. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y,
Inoue S: Efp targets 14-3-3 sigma for proteolysis and promotes breast
tumour growth. Nature 2002, 417(6891):871-875.
36. Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, Horie K, Inoue S,
Sasano H: Nuclear cyclin B1 in human breast carcinoma as a potent
prognostic factor. Cancer Sci 2007, 98(5):644-651.
37. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P,
Margreiter R, Amberger A: 14-3-3sigma expression is an independent
prognostic parameter for poor survival in colorectal carcinoma patients.
Clin Cancer Res 2005, 11(9):3274-3279.
38. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C,
Hu Z, Koch MO, et al: Loss of 14-3-3sigma in prostate cancer and its
precursors. Clin Cancer Res 2004, 10(9):3064-3068.
39. Ito K, Suzuki T, Akahira J, Sakuma M, Saitou S, Okamoto S, Niikura H,
Okamura K, Yaegashi N, Sasano H, et al: 14-3-3sigma in endometrial
cancer–a possible prognostic marker in early-stage cancer. Clin Cancer
Res 2005, 11(20):7384-7391.
40. Erovic BM, Pelzmann M, Grasl M, Pammer J, Kornek G, Brannath W, Selzer E,
Thurnher D: Mcl-1, vascular endothelial growth factor-R2, and 14-3-
3sigma expression might predict primary response against radiotherapy
and chemotherapy in patients with locally advanced squamous cell
carcinomas of the head and neck. Clin Cancer Res 2005, 11(24 Pt
1):8632-8636.
41. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Penas R,
Sanchez JM, Moran T, Camps C, Massuti B, et al: 14-3-3sigma methylation
in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-
treated advanced non-small-cell lung cancer patients predicts survival:
The Spanish Lung Cancer Group. J Clin Oncol 2005, 23(36):9105-9112.
42. Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C,
Yi H, et al: Identification of Novel Nasopharyngeal Carcinoma Biomarkers
by Laser Capture Microdissection and Proteomic Analysis. Clin Cancer Res
2008, 14(2):435-445.
43. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3Sigma
is required to prevent mitotic catastrophe after DNA damage. Nature
1999, 401(6753):616-620.
Li et al. BMC Cancer 2010, 10:598
http://www.biomedcentral.com/1471-2407/10/598
Page 10 of 11
44. Samuel T, Weber HO, Rauch P, Verdoodt B, Eppel JT, McShea A,
Hermeking H, Funk JO: The G2/M regulator 14-3-3sigma prevents
apoptosis through sequestration of Bax. J Biol Chem 2001,
276(48):45201-45206.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/598/prepub
doi:10.1186/1471-2407-10-598
Cite this article as: Li et al.: Role of 14-3-3s in poor prognosis and in
radiation and drug resistance of human pancreatic cancers. BMC Cancer
2010 10:598.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. BMC Cancer 2010, 10:598
http://www.biomedcentral.com/1471-2407/10/598
Page 11 of 11
